CDK Antibody Sampler Kit #9868
Product Information
Kit Usage Information
Protocols
- 2316: Western Blotting, Immunoprecipitation (Magnetic), Immunohistochemistry (Paraffin), Immunofluorescence, Flow, CUT&RUN Assay
- 2546: Western Blotting, Immunoprecipitation (Agarose), Flow
- 2916: Western Blotting, Immunoprecipitation (Magnetic), Immunohistochemistry (Paraffin)
- 7074: Western Blotting
- 7076: Western Blotting
- 9116: Western Blotting, Immunoprecipitation (Magnetic), Immunofluorescence
- 12790: Western Blotting, Immunohistochemistry (Paraffin), Immunofluorescence*, Flow
- 13331: Western Blotting, Immunoprecipitation (Magnetic), Immunofluorescence
Product Description
Specificity / Sensitivity
Each antibody in the CDK Antibody Sampler Kit detects endogenous levels of its respective target protein and does not cross-react with other family members.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a recombinant human cdc2 fusion protein, synthetic peptides corresponding to residues of human CDK2 and recombinant human CDK7, and residues near the carboxy terminus of human CDK4, human CDK6, and human CDK9 proteins.
Background
Cyclin-dependent kinases (CDKs) are the core effectors of cell cycle progression. CDK activity is regulated through association with their cyclin partners and cyclin-dependent kinase inhibitors (CKIs) as well as by activating and inhibitory phosphorylation events. Inhibition is mediated by Wee1 and Myt1 kinases that target residues at the amino terminus of CDK1 (1,2). Dephosphorylation of these residues by cdc25 phosphatase leads to activation of CDK kinase activity (3). The CDK7/cyclinH complex is the ubiquitous mammalian CDK-activating kinase (CAK) that phosphorylates a conserved threonine residue in the T-loop domain of CDKs. The carboxy-terminal domain of RNA polymerase II is also a target of CAK as well as CDK9/cyclinT (4,5). CDK4/6 associate with cyclinD and phosphorylate retinoblastoma protein and initiate progression through the restriction point in G1 (6). CDK2 associates with cyclinE in early S phase and cyclinA later in G2. CDK1/cyclinB regulates the initiation of mitotic events (7).
- Fattaey, A. and Booher, R.N. (1997) Prog Cell Cycle Res 3, 233-40.
- Booher, R.N. et al. (1997) J Biol Chem 272, 22300-6.
- Jessus, C. and Ozon, R. (1995) Prog Cell Cycle Res 1, 215-28.
- Kaldis, P. (1999) Cell Mol Life Sci 55, 284-96.
- De Falco, G. and Giordano, A. Cancer Biol Ther 1, 342-7.
- Sherr, C.J. (1995) Trends Biochem Sci 20, 187-90.
- Morgan, D.O. (1997) Annu Rev Cell Dev Biol 13, 261-91.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.